Further studies will be required to determine the downstream targets regulated by β-D-glucan-induced RASSF1. Likewise, the increase in ERβ mRNA in LCC9 cells treated with β-D-glucan is another logical follow-up for this study to further characterize the mechanisms by which β-D-glucan inhibits breast cancer cell proliferation in vitro. The gene discussed is RASSF1; the disease is breast cancer.